Coline Puvilland

Dr. Coline Puvilland

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2021 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
CPColine Puvilland
Coline Puvilland
BBBertrand Boisson
Bertrand Boisson
MFMathieu Fusaro
Mathieu Fusaro
JBJacinta Bustamante
Jacinta Bustamante
YBYves Bertrand
Yves Bertrand
MOMarie Ouachée-Chardin
Marie Ouachée-Chardin

22 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CPColine Puvilland
Coline Puvilland
CBCarine VILLANUEVA BOUANANI
Carine VILLANUEVA BOUANANI
AHAnaëlle Hemmendinger
Anaëlle Hemmendinger
LKLaure Kornreich
Laure Kornreich
IGIva Gueorguieva
Iva Gueorguieva
PLPierre LEBLOND
Pierre LEBLOND
There is little scientific evidence regarding the safety of GHRT in LGG, where GH deficiency is common. Purpose: to compare the recurrence rate in children with midline LGG, depending on whether or not they have received GHRT, in order to assess its impact on the risk of tumor recurrence. Methods: This bicentric retrospective study included 124 patients under the age of 18 who were diagnosed with a midline low-grade glial tumor between 1998 and 2016. We also reviewed literature on this subject. The main outcome measure was tumor relapse, demonstrated by brain MRI. Results: There were 17 patients in the GH-supplemented group (14%) and 107 patients in the non-supplemented group (86%). Relapse occurred in 65 patients (45.5%); 7 patients died (4.9%); no deaths occurred in patients receiving GHRT. Two patients developed a second tumor (1.4%), none of which had received GHRT. Relapse concerned 36.4% of patients without GHRT and 52.9% of patients with GHRT. The difference was not statistically significant between the two groups (p = 0.3). Conclusion: GHRT does not lead to a statistically significant increase in risk of relapse for pediatric midline low-grade pediatric glioma in our cohort. Although these results appear reassuring, future natural history or prospective studies should be done to ascertain these findings. Nevertheless, these reassuring data regarding GHRT are in agreement with the data in the current literature.